David Cohen has over 30 years of experience in clinical research and development, most recently as an independent consultant. He was previously the Chief Science Officer of Elutin Inc, which developed local drug delivery platforms. Prior to that, he spent 20 years at Novartis in various roles including leading drug-device combination programs and clinical evaluation teams. He has authored several patents and publications in thrombosis and cardiovascular disease.
Mohammad Arif has over 15 years of experience in clinical research and healthcare. He has extensive experience managing clinical trials from protocol development through study reporting. He has worked at The Medicines Company and Lenox Hill Hospital managing numerous cardiovascular clinical trials and studies. He has strong skills in project management, protocol development, site management, data management, and regulatory submissions.
- Kenneth W. Rundell has over 25 years of experience in regulatory affairs, medical writing, and research. He has expertise in areas such as medical writing, regulatory submissions, adverse event reporting, and electronic document management systems.
- He has a strong background managing multiple projects simultaneously and applying regulatory standards. He also has skills in areas like data management, controlled documentation, and presentation.
- Rundell has held roles as a Director of Medical Affairs and regulatory consultant. He was also a professor conducting research studies in areas like asthma, air pollution, and cardiovascular health.
Digestive Diseases Week Highlights Premier Scientific ResearchRajan Bhatt
Board certified in internal medicine and cardiology, Rajan Bhatt, MD, currently practices at Spectrum Vein Center in Scottsdale, Arizona. Active in the field of cardiology, Dr. Rajan Bhatt has delivered presentations at several medical conferences, including Digestive Diseases Week.
This document provides guidelines from the American Heart Association/American Stroke Association for the endovascular treatment of acute ischemic stroke. It analyzes results from 8 randomized clinical trials and other relevant data published since 2013. The guidelines provide recommendations for selecting patients for endovascular treatment, the endovascular procedure, and systems of care to facilitate endovascular treatment. Certain endovascular procedures using new devices like stent retrievers have been shown to provide clinical benefits in some patients with acute ischemic stroke when performed at high-volume centers with experienced staff.
El documento habla sobre el tiempo que los padres dedican a sus hijos. Señala que a menudo los padres se enfocan demasiado en lograr un alto estatus socioeconómico y mantener un nivel superior en el trabajo, lo que les hace olvidarse de la educación de sus hijos. También menciona la importancia de promover comportamientos saludables en la familia a través de temas como asistencia técnica en eventos sociales para ayudar a crear una buena familia y estilos de vida saludables.
Presentación de derecho mercaltil I. siury pinedasiurypineda
La letra de cambio es un documento mercantil en el que una persona (librador) ordena el pago de una cantidad de dinero a otra persona (librado) en una fecha determinada. La letra de cambio tiene varios sujetos clave como el librador, librado y aceptante, y requisitos legales como la indicación de la fecha de vencimiento, beneficiario y firmas. Sirve para realizar pagos entre empresas de manera segura.
El documento describe el Sistema Nacional de Información de Seguridad Pública de México. Su objetivo es combatir el delito y garantizar la confiabilidad de los trabajadores de seguridad pública mediante la recopilación y almacenamiento de información de diez bases de datos nacionales que incluyen información de los tres niveles de gobierno. El sistema permite identificar plenamente a los miembros del personal de seguridad pública y registrar sus antecedentes de manera permanente para prevenir la contratación de personas no confiables.
MSSanté : point d’étape sur le déploiement du service et présentation du dispositif de communication - Vladimir VILTER, Olivier BECANNE et David PETAUTON, ASIP Santé
Mohammad Arif has over 15 years of experience in clinical research and healthcare. He has extensive experience managing clinical trials from protocol development through study reporting. He has worked at The Medicines Company and Lenox Hill Hospital managing numerous cardiovascular clinical trials and studies. He has strong skills in project management, protocol development, site management, data management, and regulatory submissions.
- Kenneth W. Rundell has over 25 years of experience in regulatory affairs, medical writing, and research. He has expertise in areas such as medical writing, regulatory submissions, adverse event reporting, and electronic document management systems.
- He has a strong background managing multiple projects simultaneously and applying regulatory standards. He also has skills in areas like data management, controlled documentation, and presentation.
- Rundell has held roles as a Director of Medical Affairs and regulatory consultant. He was also a professor conducting research studies in areas like asthma, air pollution, and cardiovascular health.
Digestive Diseases Week Highlights Premier Scientific ResearchRajan Bhatt
Board certified in internal medicine and cardiology, Rajan Bhatt, MD, currently practices at Spectrum Vein Center in Scottsdale, Arizona. Active in the field of cardiology, Dr. Rajan Bhatt has delivered presentations at several medical conferences, including Digestive Diseases Week.
This document provides guidelines from the American Heart Association/American Stroke Association for the endovascular treatment of acute ischemic stroke. It analyzes results from 8 randomized clinical trials and other relevant data published since 2013. The guidelines provide recommendations for selecting patients for endovascular treatment, the endovascular procedure, and systems of care to facilitate endovascular treatment. Certain endovascular procedures using new devices like stent retrievers have been shown to provide clinical benefits in some patients with acute ischemic stroke when performed at high-volume centers with experienced staff.
El documento habla sobre el tiempo que los padres dedican a sus hijos. Señala que a menudo los padres se enfocan demasiado en lograr un alto estatus socioeconómico y mantener un nivel superior en el trabajo, lo que les hace olvidarse de la educación de sus hijos. También menciona la importancia de promover comportamientos saludables en la familia a través de temas como asistencia técnica en eventos sociales para ayudar a crear una buena familia y estilos de vida saludables.
Presentación de derecho mercaltil I. siury pinedasiurypineda
La letra de cambio es un documento mercantil en el que una persona (librador) ordena el pago de una cantidad de dinero a otra persona (librado) en una fecha determinada. La letra de cambio tiene varios sujetos clave como el librador, librado y aceptante, y requisitos legales como la indicación de la fecha de vencimiento, beneficiario y firmas. Sirve para realizar pagos entre empresas de manera segura.
El documento describe el Sistema Nacional de Información de Seguridad Pública de México. Su objetivo es combatir el delito y garantizar la confiabilidad de los trabajadores de seguridad pública mediante la recopilación y almacenamiento de información de diez bases de datos nacionales que incluyen información de los tres niveles de gobierno. El sistema permite identificar plenamente a los miembros del personal de seguridad pública y registrar sus antecedentes de manera permanente para prevenir la contratación de personas no confiables.
MSSanté : point d’étape sur le déploiement du service et présentation du dispositif de communication - Vladimir VILTER, Olivier BECANNE et David PETAUTON, ASIP Santé
La letra de cambio es un documento mercantil mediante el cual una persona, llamada librador, ordena a otra, el librado, el pago de una cantidad de dinero en una fecha determinada. Los sujetos de la letra de cambio son el librador, librado, beneficiario y fiador. Debe contener ciertos requisitos como la orden de pago, la cantidad, el lugar y fecha de pago. Si no es pagada, el beneficiario puede iniciar una acción cambiaria directa contra el librado o de regreso contra otros sujetos como el librador o fiador.
Introduction of magnetic separator 20111116-yydlsFelicity Yuan
Yueyang Dalishen Electromagnetic Machinery Co., Ltd. is a leading manufacturer of electromagnetic equipment in Asia-Pacific. They produce 10 series of 200 magnetic separation products. The Double Vertical Ring High Gradient Magnetic Separator DLS is their flagship product. It uses rotating rings with magnetic rods to generate a high gradient magnetic field for separating weakly magnetic minerals. The DLS provides high enrichment ratios, flexibility in particle sizes and pulp densities, and high recovery rates.
Natural gas is a combustible mixture of hydrocarbon gases that is primarily composed of methane but can also contain ethane, propane, butane, and pentane. It is formed naturally underground and is considered a nonrenewable fossil fuel. Some key advantages of natural gas are that it is one of the cleanest, safest, and most useful energy sources; it burns cleanly without producing ash or smoke; and it can be transported via pipelines. Natural gas is widely used as a fuel for cooking, heating homes and buildings, generating electricity, fueling vehicles, and various industrial processes.
Sales is, at its core, a communication-based business. After all, if customers could make an informed purchase decision without communication, there would be no sales people. Learn five essential strategies for success in sales communication that you can apply to improve sales results today.
Space Qualified Resistors From Vishay Foil Resistors A VPG BrandRick Grigalunas
Space,Avionics and Military Metal Foil Resistors Providing Flawless Performance When Required. Products include Chip Resistors, Potentiometers, HermeticallySealed Networks and much more.
This curriculum vitae summarizes the career and qualifications of Richard L. Wurdeman. He has over 30 years of experience in clinical research, pharmacy practice, and pharmaceutical sales. Currently he works as a Senior Scientific Liaison for Janssen Scientific Affairs, and previously held roles in clinical research and as a Regional Scientific Manager for AstraZeneca. He has authored several peer-reviewed publications and presentations on cardiovascular topics.
This document provides a summary of Patti E. Dawson's professional experience in clinical research and medical product development spanning over 30 years. Recent roles include Director of Clinical Research at Brain Sentinel from 2012-2014 where she managed multiple clinical studies for a seizure detection device. Prior experience includes research project management positions at Brooke Army Medical Center in 2012 and Director of Clinical Research at CryoLife from 2006-2009 where she managed clinical studies for various tissue allograft products. She has extensive experience in pre-clinical research, clinical trial execution, regulatory submissions, and product development.
Raymond J. Winquist is an experienced research leader with over 30 years of experience in drug discovery. He has held senior leadership roles at several large pharmaceutical companies and biotechs, managing departments with budgets over $25 million. His expertise is in pharmacology, molecular and cellular biology, and overseeing diverse research platforms. He has progressed multiple drug candidates into clinical trials across various therapeutic areas such as oncology, neurology, and inflammation.
This curriculum vitae summarizes the educational background and professional experience of Ryan D. Russell, Ph.D. He received a B.S. in Biomedical Science from Marquette University in 2002 and a Ph.D. in Kinesiology from Louisiana State University in 2011. His current position is as a Junior Research Fellow at the Menzies Institute for Medical Research in Tasmania, Australia, where he coordinates and runs clinical trials related to diabetes. He has extensive experience in clinical research related to exercise interventions for diabetes and microvascular health.
The document summarizes a Sino-American symposium on clinical and translational research held in Beijing, China from June 16-18, 2010. The symposium was co-organized by the Chinese Academy of Medical Sciences, GlobalMD organization, and the US National Institutes of Health Clinical Center. It focused on building collaboration and communication between US and China in clinical and translational research. Over the three days, there were keynote speeches, panels, and sessions on various topics in global health research, infectious diseases, bioethics, and more. The goal was to foster US-China collaboration in research, education, innovation, and improving global healthcare.
Rong Chen is an expert in clinical genome informatics with 16 years of experience. He has built clinical genome informatics teams at Mount Sinai and Personalis. He has launched startups and developed NGS products for precision medicine. He has published over 70 papers and invented many patents. He received his Ph.D. from Boston University and has held positions at various academic and industry research laboratories.
Homa Assar has over 15 years of experience as a technical writer and editor for the National Cancer Institute and NIH. She has expertise in writing for clinical trials, FDA regulations, and informed consent forms. Her experience also includes maintaining databases, translating medical documents, and authoring scientific publications. She is highly skilled in English, Persian, French, Italian, and German.
This document outlines the accomplishments and career of Venkatakrishna Shyamala, PhD. She has held senior research and development roles at several companies developing molecular diagnostic technologies, including Innovative Biosensors, Inc., Digene Corporation, and Chiron Corporation. She has also consulted for Research Diagnostics, Inc. and Novartis Diagnostics on nucleic acid testing assays for blood screening. Additionally, she has authored several publications in peer-reviewed journals and contributed to Clinical & Laboratory Standards Institute documents on molecular diagnostics best practices.
This document outlines the accomplishments and career of Dr. Venkatakrishna Shyamala. She has over 30 years of experience in research and development roles, including positions at Chiron Corporation, Digene Corporation, Innovative Biosensors Inc., and as a consultant. Her work has focused on developing and validating nucleic acid-based assays for infectious diseases like HIV, HCV, HBV, and WNV. She has published numerous papers on these assays and their analytical performance and has contributed to regulatory documents on molecular diagnostics.
CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of technology demonstrations and dinner courses.
H.V. Mendenhall has over 40 years of experience in preclinical surgery. He received his PhD in Experimental Surgery from Colorado State University in 1981 and his DVM from Colorado State University in 1968. Currently, he works as a consultant in preclinical surgery, assisting sponsors with study designs, protocols, and performing surgical procedures for medical device testing. He has held various roles such as Director of Preclinical Translational Services and Principal Scientist, where he oversaw surgical facilities and training. Mendenhall has extensive experience conducting preclinical studies for medical device development and FDA approval.
This document provides an overview and learning objectives for an issue of Continuum: Lifelong Learning in Neurology focused on spinal cord disorders. The issue aims to help neurologists stay up-to-date in their knowledge and skills for defining spinal cord syndromes, interpreting MRI findings, recognizing common spinal cord disorders, and managing related complications. Specific topics covered include cervical spondylosis, vascular disorders, infections, autoimmune conditions, neoplasms, and cauda equina syndrome.
This document provides information about a book titled "Gland-Preserving Salivary Surgery: A Problem-Based Approach". It includes a foreword describing the development and importance of minimally invasive and gland-preserving treatments for salivary gland diseases. It also lists the editors of the book and their contributions to advancing techniques like sialendoscopy. The book provides a comprehensive overview of modern diagnostic and treatment methods for salivary gland disorders from experienced clinicians.
This document is a curriculum vitae for Dr. Ryan D. Russell that outlines his education, appointments, honors, grants, and teaching experience. The key points are:
- Dr. Russell received his Ph.D. in Kinesiology from Louisiana State University in 2011 and is currently a Junior Research Fellow at the Menzies Institute for Medical Research in Tasmania, Australia.
La letra de cambio es un documento mercantil mediante el cual una persona, llamada librador, ordena a otra, el librado, el pago de una cantidad de dinero en una fecha determinada. Los sujetos de la letra de cambio son el librador, librado, beneficiario y fiador. Debe contener ciertos requisitos como la orden de pago, la cantidad, el lugar y fecha de pago. Si no es pagada, el beneficiario puede iniciar una acción cambiaria directa contra el librado o de regreso contra otros sujetos como el librador o fiador.
Introduction of magnetic separator 20111116-yydlsFelicity Yuan
Yueyang Dalishen Electromagnetic Machinery Co., Ltd. is a leading manufacturer of electromagnetic equipment in Asia-Pacific. They produce 10 series of 200 magnetic separation products. The Double Vertical Ring High Gradient Magnetic Separator DLS is their flagship product. It uses rotating rings with magnetic rods to generate a high gradient magnetic field for separating weakly magnetic minerals. The DLS provides high enrichment ratios, flexibility in particle sizes and pulp densities, and high recovery rates.
Natural gas is a combustible mixture of hydrocarbon gases that is primarily composed of methane but can also contain ethane, propane, butane, and pentane. It is formed naturally underground and is considered a nonrenewable fossil fuel. Some key advantages of natural gas are that it is one of the cleanest, safest, and most useful energy sources; it burns cleanly without producing ash or smoke; and it can be transported via pipelines. Natural gas is widely used as a fuel for cooking, heating homes and buildings, generating electricity, fueling vehicles, and various industrial processes.
Sales is, at its core, a communication-based business. After all, if customers could make an informed purchase decision without communication, there would be no sales people. Learn five essential strategies for success in sales communication that you can apply to improve sales results today.
Space Qualified Resistors From Vishay Foil Resistors A VPG BrandRick Grigalunas
Space,Avionics and Military Metal Foil Resistors Providing Flawless Performance When Required. Products include Chip Resistors, Potentiometers, HermeticallySealed Networks and much more.
This curriculum vitae summarizes the career and qualifications of Richard L. Wurdeman. He has over 30 years of experience in clinical research, pharmacy practice, and pharmaceutical sales. Currently he works as a Senior Scientific Liaison for Janssen Scientific Affairs, and previously held roles in clinical research and as a Regional Scientific Manager for AstraZeneca. He has authored several peer-reviewed publications and presentations on cardiovascular topics.
This document provides a summary of Patti E. Dawson's professional experience in clinical research and medical product development spanning over 30 years. Recent roles include Director of Clinical Research at Brain Sentinel from 2012-2014 where she managed multiple clinical studies for a seizure detection device. Prior experience includes research project management positions at Brooke Army Medical Center in 2012 and Director of Clinical Research at CryoLife from 2006-2009 where she managed clinical studies for various tissue allograft products. She has extensive experience in pre-clinical research, clinical trial execution, regulatory submissions, and product development.
Raymond J. Winquist is an experienced research leader with over 30 years of experience in drug discovery. He has held senior leadership roles at several large pharmaceutical companies and biotechs, managing departments with budgets over $25 million. His expertise is in pharmacology, molecular and cellular biology, and overseeing diverse research platforms. He has progressed multiple drug candidates into clinical trials across various therapeutic areas such as oncology, neurology, and inflammation.
This curriculum vitae summarizes the educational background and professional experience of Ryan D. Russell, Ph.D. He received a B.S. in Biomedical Science from Marquette University in 2002 and a Ph.D. in Kinesiology from Louisiana State University in 2011. His current position is as a Junior Research Fellow at the Menzies Institute for Medical Research in Tasmania, Australia, where he coordinates and runs clinical trials related to diabetes. He has extensive experience in clinical research related to exercise interventions for diabetes and microvascular health.
The document summarizes a Sino-American symposium on clinical and translational research held in Beijing, China from June 16-18, 2010. The symposium was co-organized by the Chinese Academy of Medical Sciences, GlobalMD organization, and the US National Institutes of Health Clinical Center. It focused on building collaboration and communication between US and China in clinical and translational research. Over the three days, there were keynote speeches, panels, and sessions on various topics in global health research, infectious diseases, bioethics, and more. The goal was to foster US-China collaboration in research, education, innovation, and improving global healthcare.
Rong Chen is an expert in clinical genome informatics with 16 years of experience. He has built clinical genome informatics teams at Mount Sinai and Personalis. He has launched startups and developed NGS products for precision medicine. He has published over 70 papers and invented many patents. He received his Ph.D. from Boston University and has held positions at various academic and industry research laboratories.
Homa Assar has over 15 years of experience as a technical writer and editor for the National Cancer Institute and NIH. She has expertise in writing for clinical trials, FDA regulations, and informed consent forms. Her experience also includes maintaining databases, translating medical documents, and authoring scientific publications. She is highly skilled in English, Persian, French, Italian, and German.
This document outlines the accomplishments and career of Venkatakrishna Shyamala, PhD. She has held senior research and development roles at several companies developing molecular diagnostic technologies, including Innovative Biosensors, Inc., Digene Corporation, and Chiron Corporation. She has also consulted for Research Diagnostics, Inc. and Novartis Diagnostics on nucleic acid testing assays for blood screening. Additionally, she has authored several publications in peer-reviewed journals and contributed to Clinical & Laboratory Standards Institute documents on molecular diagnostics best practices.
This document outlines the accomplishments and career of Dr. Venkatakrishna Shyamala. She has over 30 years of experience in research and development roles, including positions at Chiron Corporation, Digene Corporation, Innovative Biosensors Inc., and as a consultant. Her work has focused on developing and validating nucleic acid-based assays for infectious diseases like HIV, HCV, HBV, and WNV. She has published numerous papers on these assays and their analytical performance and has contributed to regulatory documents on molecular diagnostics.
CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of technology demonstrations and dinner courses.
H.V. Mendenhall has over 40 years of experience in preclinical surgery. He received his PhD in Experimental Surgery from Colorado State University in 1981 and his DVM from Colorado State University in 1968. Currently, he works as a consultant in preclinical surgery, assisting sponsors with study designs, protocols, and performing surgical procedures for medical device testing. He has held various roles such as Director of Preclinical Translational Services and Principal Scientist, where he oversaw surgical facilities and training. Mendenhall has extensive experience conducting preclinical studies for medical device development and FDA approval.
This document provides an overview and learning objectives for an issue of Continuum: Lifelong Learning in Neurology focused on spinal cord disorders. The issue aims to help neurologists stay up-to-date in their knowledge and skills for defining spinal cord syndromes, interpreting MRI findings, recognizing common spinal cord disorders, and managing related complications. Specific topics covered include cervical spondylosis, vascular disorders, infections, autoimmune conditions, neoplasms, and cauda equina syndrome.
This document provides information about a book titled "Gland-Preserving Salivary Surgery: A Problem-Based Approach". It includes a foreword describing the development and importance of minimally invasive and gland-preserving treatments for salivary gland diseases. It also lists the editors of the book and their contributions to advancing techniques like sialendoscopy. The book provides a comprehensive overview of modern diagnostic and treatment methods for salivary gland disorders from experienced clinicians.
This document is a curriculum vitae for Dr. Ryan D. Russell that outlines his education, appointments, honors, grants, and teaching experience. The key points are:
- Dr. Russell received his Ph.D. in Kinesiology from Louisiana State University in 2011 and is currently a Junior Research Fellow at the Menzies Institute for Medical Research in Tasmania, Australia.
The Midwest Stroke Action Alliance recently hosted a panel of health experts on the risks of venous thromboembolism (VTE which is commonly referred to as blood clots).
The health experts on the panel were:
- Mark J. Alberts, MD (Clinical Vice-Chair for Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center)
- Laurie Paletz, BSN, PHN, RN-BC (Stroke Program Coordinator, Cedars-Sinai Medical Center)
- Michael W. Wong, JD (Executive Director, Physician-Patient Alliance for Health & Safety)
Stroke is a leading cause of death and disability in the U.S., with 800,000 cases occurring each year. Each year in the United States, an estimated 300,000 cases of VTE occur. Mortality can be as high as 3.8 percent in patients with deep vein thrombosis (DVT) and 38.9 percent in those with pulmonary embolism (PE). VTE is associated with a high risk of death in the U.S. and Europe, with an estimated incidence rate of 1 in 1,000 patients. VTE is particularly common after a stroke. Approximately 20 percent of hospitalized immobile stroke patients will develop DVT, and 10 percent a PE.
Dr. Nancy Louis Wassef has over 30 years of experience in clinical pathology and laboratory management. She has held leadership roles as the Head of Pathology Departments and Laboratories in the UK, Saudi Arabia, and Europe. Her expertise includes clinical chemistry, hematology, microbiology, and transfusion medicine. She has published over 30 medical papers and is fluent in English, French, and Arabic.
This document provides information about an upcoming pediatric cardiology conference to be held September 22-24, 2016 in Las Vegas, Nevada. It includes details about the conference theme, organizers, keynote speakers, sessions, and registration. The welcome message is from Professor Guy Hugues Fontaine, a famous cardiologist, who discusses his background and contributions to the field. The document outlines the conference agenda over the three days, with 15 tracks covering topics in pediatric cardiology, heart surgery, critical care, and more.
69th ICREA Colloquium "Everything you always wanted to know about creating a ...ICREA
Everything you always wanted to know about creating a company (but were afraid to ask) - Joan Seoane (ICREA at VHIO)
Why would you, decent and exemplary ICREA researchers, ever want to get involved in the creation of a spin-off company? In this colloquium we will take a stroll on the ‘dark side of science’: its commercial exploitation. The talk aims at covering both the practical and the institutional points of view. To that end, Joan Seoane, who started his own company ‘Mosaic Biomedicals’ in 2012, will share his experience with all of us. And Emilià Pola will present the vision and the position of ICREA as an institution, or in other words, why an institution like ICREA gets involved in such mundane activities.
69th ICREA Colloquium "Everything you always wanted to know about creating a ...
David S.Cohen-Curriculum Vitae
1. David S. Cohen Ph.D. Curriculum Vitae 1
Curriculum Vitae
David S. Cohen, Ph.D.
10008 Alegria Drive, Las Vegas, NV 89144
Mobile: (908) 723-7337
Email: sssumnconsulting@gmail.com
Employment History:
David S. Cohen Ph.D., Consulting, Las Vegas, NV 2011 - Present
Site-Specific Solutions for Unmet Medical Needs Consulting, LLC: Proposing site-specific, local
treatment modalities in the areas of cardiovascular and peripheral arterial disease, oncology,
orthopedics, and gynecology. Liasoning with medical device, drug delivery, pharmaceutical, and
biotech companies to provide adjunctive therapeutic options or platforms from which to package
and carry a therapy to the desired physiological site.
Elutin Inc. and Elutin Vascular Inc., Las Vegas, NV 2013 – 2015
Co-Founder, President and Chief Science Officer
Elutin was a Medical Technology company predicated on developing patent-protected, site-specific,
local therapies delivering ‘outside the biological tube’ therapeutic deliverable biodegradable
platforms for the treatment of unmet or inadequately met medical needs in the areas of peripheral
arterial disease, end-stage renal disease, oncology, orthopedics, central nervous system disorders
and erectile dysfunction.
2. David S. Cohen Ph.D. Curriculum Vitae 2
COHENMedical, LLC , Boonton, NJ 2011 -2013
Founder and Chief Science Officer
Development of local, site-specific drug delivery platforms to patients with advanced peripheral
arterial disease and its most severe manifestation, Critical limb Ischemia. The company was sold in
August 2013.
Novartis Pharmaceuticals Corp, East Hanover, NJ
Principal Medical Scientific Expert/ Co-Leader of the Novartis Drug-Eluting Device
Program 2001 - 2011
Identified and determined the feasibility of diverse medical device company platforms for
cardiovascular and non-cardiovascular drug-delivery applications. Identified and recommended
drugs of varying mechanisms of action for local drug delivery therapy platforms such as drug -
eluting stents, vascular access grafts, surgical wraps and meshes, orthopedic and ocular implants,
anti-arrhythmic and intra-ventricular assist devices, anti-embolic CABG platforms, passive cardiac
assist devices, bronchial stents, and otolaryngology applications. To date, nine companies have or
had out-licensing agreements with Novartis from which three platforms have attained regulatory
approval or were or are currently in clinical trials.
Principal Medical Scientific Expert in Cardiovascular/Metabolism Research and
Development 2004 - 2011
Led and/or conducted clinical ‘due diligence’ evaluation teams for the Business, Development and
Licencing and Mergers and Acquisitions groups for in-licensing candidates in vascular,
antithrombotic, antihypertensive, anti-diabetic and anti-obesity indications. These included the anti-
platelet agent Elinogrel, the anticoagulants Rivaroxiban (Xeralto@
), Apixaban (Eliquis@
) and
Dabigatran (Pradexa@
), recombinant Relaxin (Serelaxin@
) for acute decompensated heart failure,
and recombinant Human Elastase to enhance maturation and function of venous-arterial fisulas in
renal hemodialysis. Planning and design member of numerous Clinical Trial Teams, assisting in
protocol development and review, and regulatory planning. Coordinated DSM/DSMBs. Reviewer
of manuscripts for numerous journals such as Thrombosis Research, The Journal of Cardiovascular
Pharmacology, The European Journal of Interventional Cardiology and Cardiovascular
Therapeutics (formerly Cardiovascular Drug Reviews).
Lotrel Clinical Research Manager/Publication Manager 2003 - 2004
ACCOMPLISH (Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving
with Systolic Hypertension) Data Safety Management Board coordinator. Member of the
ACCOMPLISH megatrial trial team and co-clinical trial leader of the Lotrel superiority trial.
Oversaw all Lotrel publication strategies. Composed manuscripts and abstracts of clinical trial
protocols, data, and final reports
3. David S. Cohen Ph.D. Curriculum Vitae 3
Executive Director/International Project Team Leader 2001 - 2003
Led two cholesterol lowering ‘Statin’ projects in the Novartis Cardiovascular/Metabolism Project
Management group: Lescol (Fluvastatin) involving Life Cycle Management, Phase 4 post-
marketing studies; and Pitavastatin in phase 2 and 3 development. Oversaw the Pitavastatin
tetrapartide (Novartis, Nissan Pharma, Sankyo Pharma and Kowa Pharma) decision board.
Distinguished Research Fellow, Cardiovascular/Metabolic Research 2000 -2001
Preclinical Therapeutic Area leader and Representative to Project Management and Translational
Medicine. Responsible for critical evaluations of internal and external opportunities and subsequent
‘shepherding’ from preclinical to Phase 2A clinical studies.
Principal Fellow, Cardiovascular Research 1996 - 2000
Led preclinical, drug discovery research groups (4-10 scientists) in the areas of renal disease,
cardioprotection, hypertension, thrombosis, lipid regulation and modulating strategies, and anti-
diabetic projects (PPAR agonists, GLP-1 analogs, DPP-4 antagonists, etc.).
Ciba Pharmaceuticals Corp., Summit, NJ
Senior Fellow 1992 - 1996
Senior Research Scientist 1988 - 1992
Research Scientist 1984 - 1988
Post-Doctoral Fellow 1982 - 1984
Doctoral Candidate, Univ. MA School of Medicine, Worcester and Boston, MA 1977 - 1982
Research Associate, Special Hematology, Columbia Univ. College of Physicians & Surgeons, NY, NY
1974-1977
Adjunct Lecturer in Biology, City University of New York, NY 1972 -1975
Clinical/Preclinical Research and Development and Project Management
Experience:
• Invited Speaker: University of Medicine and Dentistry of New Jersey (Topic: New
Antithrombotics: Arterial meets Venous, finally east meets west………’what a bloody mess!’)
• Guest lecturer (Topic: Device mediated local drug delivery: future paradigms) at Bruce
Rappaport Medical School, Haifa, Israel and Hebrew University of Jerusalem, Hadassah
Medical School, Israel.
• Novartis Expert to Promus Element DES FDA advisory panel
• Novartis Expert to Xience V DES FDA advisory panel.
4. David S. Cohen Ph.D. Curriculum Vitae 4
• Presented ‘Local Drug Delivery’ opportunities at IM4 Vancouver conference.
• Chaired ‘future antithrombotics’ workshop.
• Presenter at IM3 Medical Device Company Forum on “synergies between ‘Big Pharma’ and site-
specific local drug delivery”.
• Participant in thrombosis expert advisory panel.
• Participant in forum on diabetic cardiovascular disease (clinical manifestations,
mechanistic approaches, future market trends).
• Led six Deal Evaluation teams examining opportunities in dyslipidemia and thrombosis.
• Strategic representative on four additional Deal Evaluation Teams.
• Thrombosis expert on Prexige (COX-2 Inhibitor) International Project Teams.
• Metabolic/Cardiovascular Disease representative to four International Project Teams.
• Research representative to the ‘Proof of Research in Development’ Team (Project Mgmt).
• Member of the Cardio-Renal International Project Team.
• Member of Novartis Due-Diligence/Deal Evaluation Thrombosis/Hypertension in-licensing
program.
• Member of Novartis’ Cardiovascular Disease Task Force on Restenosis and Thrombosis.
• Member of the Ciba International Strategic Alignment Committee on Renal Disease.
• Leading Scientist in Ciba/Novartis research efforts in the study of chronic renal disease.
• Member of the Ciba Thrombosis Strategic Alignment Team.
• Ciba-Geigy Research Coordinator of the Queen’s University (Kingston, Ontario, Canada)
Nitric Oxide Donor synthetic and pharmacology project.
• U.S. Project Team Leader of Nitric Oxide Donor Project.
• Development Project Team Member, Preclinical Research Project leader for CGS 22652
(dual thromboxane antagonist/thromboxane synthase inhibitor) and REVASC (rec-Hirudin).
• Composed preclinical sections (section 6A) of nine IND submissions.
• Project Leader, Dual Thromboxane Antagonist/Thromboxane Synthase Inhibitor Project.
• Aided in the ‘startup’ of a new research group in platelet function/inhibition.
• Conducted research in thrombosis, coagulopathies. hypertension, renal disease, and heart failure
Career Development:
• George Washington University/ESI Program in Project Management
• Novartis Global Project Management Workshop, Princeton, NJ.
• Novartis Global Project Management Workshop, Basel, Switzerland.
• Global Novartis Research Conference, Florence, Italy.
• Immunologically Mediated Atherogenesis Workshop, Vienna, Austria.
• PRIDE (Proof of Research in Development) International Workshop, Basel, Switzerland.
• Principles of Preclinical and Clinical Safety Workshop, Paris, France.
• Product Life-Cycle Management Workshop, Basel, Switzerland.
• Diversity Training Workshop, Morristown, NJ.
• Research Project Team Member Workshop, Murray Hill, NJ.
• Project Team Effectiveness Workshop, Princeton, NJ.
• Project Team Management Workshop, Princeton, NJ.
• Advanced Statistics for the Pharmaceutical Scientist New Brunswick, NJ.
5. David S. Cohen Ph.D. Curriculum Vitae 5
Patent and Invention Disclosures:
D.S. Cohen. Site specific drug delivery wraps, systems and methods of use thereof related
applications. U.S. Patent Application No. 14/181,353 (based on 61/765,842), International
Application No. PCT/US14/16568, Filed 2014
D.S. Cohen. Site specific drug delivery wraps, systems and methods of use thereof. Application
Ser. No. 61/765,842 filed 2013.
D.S. Cohen. A pharmaceutical composition comprising LBM 642 and other PPARα/γ agonists
alone and in combination with other active ingredients as elutants from dug-releasing intravascular
devices to prevent reocclusion. Case 4-32165P1/USN, filed 2004.
D.S. Cohen. A pharmaceutical composition comprising PDE5 inhibitors and other active
ingredients for the treatment of male erectile dysfunction in hypertensive, diabetic, dyslipidemic
and depressed patients. Case 4-32165B/USN, filed 2004.
D.S. Cohen. Devices and methods for delivering MMP inhibitors. Case 4-3289A/USN, filed 2003.
D.S. Cohen. Multiple combinations of multiple antihypertensive agents and aldosterone
modulators. 4-32165A/USN, filed 2002.
D.S. Cohen and A.J. Trapani. Treatment of chronic progressive renal failure with CGS 30440.
Patent Docket - 4-20590/P1/CGC 1830/Prov, filed 1995.
M. deGasparo, R.L. Webb and D.S. Cohen. A pharmaceutical combination composition (benazepril
+ valsartan) for the treatment of hypertension, congestive heart failure and renal failure. Patent
Docket - 4-20402A, filed 1995.
D.S.Cohen. Use of CGS 22652 and analogs thereof, selective dual thromboxane rececptor
antagonists/thromboxane synthase inhibitors, for the prtevention of arterial thrombosis following
intravascular procedures. Patent Docket – 3-87907/USN, filed 1993.
D.S. Cohen and G.R. Marx. Use of novel nitric oxide donors for the treatment of angina,
pulmonary hypertension, and acute respiratory distress syndrome. Patent Docket – 3-64813/CGC
1586/Prov, filed 1992.
G.R. Marx and D.S. Cohen. Use of novel nitric oxide donors for the treatment of angina,
pulmonary hypertension, and acute respiratory distress syndrome. Can. Patent – 1,295,643.
IND Submissions (Section 6A) and NDA contributions:
QAD 163, Phosphodiesterase 5 inhibitor for erectile dysfunction
CGP 60536, Alliskirin, Renin antagonist
Amlopdipine/Valsartan, fixed combination of calcium channel blocker/ARB for hypertension
6. David S. Cohen Ph.D. Curriculum Vitae 6
CGS 30440, Vasopeptidase Inhibitor
CGP 48933, Valsartan, Angiotensin receptor antagonist
CGP 42112A, Angiotensin receptor antagonist (AT2)
CGS 24267A, Lotrel, Amlodipine plus Lotensin for hypertension
CGS 14824, Angiotensin Converting Enzyme Inhibitor
CGP 39393, recombinant Hirudin, Thrombin Inhibitor-antithrombotic
CGS 23305, Thromboxane Synthetase Inhibitor/Thromboxane Receptor Antagonist
CGS 22652, Thromboxane Synthetase Inhibitor/Thromboxane Receptor Antagonist
CGS 12970, Thromboxane Synthetase Inhibitor
CGS 13080, Thromboxane Synthetase Inhibitor
Invited Conference Participant :
• Presenter of Elutin Inc at AZ Bio Angel/Venture Capital Conference, Phoenix, AZ, 2015
• University of Nevada, Las Vegas Entrepreneurs Student Workshop, Las Vegas, NV 2013
• Drew University Symposium on Careers in Pharmaceutical Sciences, Madison, NJ, 2011
• Co-chaired American Society of Thrombosis satellite session, Las Vegas, NV, 2009
• Presented ‘Local Drug Delivery’ opportunities at IM4 Vancouver conference, 2007.
• Chaired ‘future antithrombotics’ workshop, MIT University, 2007.
• Presenter at IM3 Medical Device Company Forum on “synergies between Big Pharma and the
Medical Device Industry; opportunities for site-specific local drug delivery”, 2006.
• Co-Chairman of Antithrombotic Key Opinion Leader In-licensing Strategy Workshop, NewYork,
NY, 2005.
• Co-Chairman of Thrombosis Disease Strategy, Key Opinion Leader Advisory Board, Cambridge,
MA, 2004.
• Co-chairman of Drug-Eluting Stent, Key Opinion Leader Advisory Board, Cambridge, MA, 2004.
• Third International Symposium on Angiotensin Antagonism, London, UK, 2000.
• Second International Symposium on Angiotensin Antagonism, London, UK, 1999.
• Nitric Oxide in Health and Disease, Philadelphia, PA, 1993.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Lucerne,
Switzerland, 1993.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Horsham, UK,
1991.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Princeton, NJ,
1989.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Interlaken,
Switzerland, 1987.
• American Heart Association Satellite Symposium on Thromboxane Synthase Inhibition, Dallas,
TX, 1983.
7. David S. Cohen Ph.D. Curriculum Vitae 7
Society Memberships:
Nevada/Bio Governor’s office Working Group
Clarke County, NV Science and Technology Interdisciplinary Committee
European Society of Cardiology
The American Association for the Advancement of Science
The International Society of Thrombosis and Haemostasis
The American Council on Thrombosis
The New York Academy of Sciences
The American Heart Association
The American Society on Hypertension.
American Diabetes Association.
International Academy of Clinical and Applied Thrombosis/Hemostasis
American Society of Interventional Cardiology
Honorariums:
Fellow, International Society of Clinical and Applied Thrombosis
Fellow, American Society on Thrombosis
Fellow, The Society of Clinical and Applied Hypertension
Strathmore’s ‘Who’s Who’
Volunteer Experience:
Special Olympics of New Jersey, Baseball Coach
Association for the Help of Retarded Children, Bronx, NY and Livingston, NJ
Morris County, NJ Young Men’s Mentor Program
Fountain House, New York, NY
The Bowery Rescue Mission
Union County, NJ Food Bank
Three Square Food Bank, Las Vegas, NV
Youth Baseball Coach, Ramapo, NY and New Providence, NJ
Education:
Ph.D. University of Massachusettes School of Medicine, Worcester, MA
Thesis: Oxygen free radical-induced platelet and progenitor megakaryocyte membrane alterations:
effects on arterial thrombosis, flow mechanics and intra-arterial inflammation.
M.S. City University of New York, NY.
B.S. Biology, City College of New York, N.Y.
8. David S. Cohen Ph.D. Curriculum Vitae 8
Publications:
1. D.S. Cohen, J.E. Mathis, R.A. Dotson and Z. Stephan. The antiobesity and lipid altering actions of chronic
microsomal transport protein (MTP) inhibition in obese Zucker rats. Cardiovasac. Diabetology 2: 43-49,
2003.
2. Cohen, D.S. Dotson, R.A., Gagen, K.S., Webb, R.L., Trapani, A.J., Fink, C.A. Vasopeptidase Inhibition
improves renal function and reduces cardiac hypertrophy in rats with reduced renal mass. Cardiovasc. Res.
56: 15-21, 2002.
3. D. S. Cohen, J.E. Mathis, R.A. Dotson, S.R. Graybill and J.L. Robertson. Endothelin A/B receptor
antagonism improves renal function in chronic cyclosporine nephrotoxicity. Endothelin-Seventh Int Cong,
2001.
4. D.S. Cohen, J.E. Mathis, R.A. Dotson, S.R. Graybill and J.L. Robertson. The combination of angiotensin II
receptor antagonism with angiotensin converting enzyme inhibition in the rat remnant kidney model:
benefits over monotherapy. 4th
International Symposium on Angiotensin Antagonism, London, UK, 2001.
5. D.S. Cohen, C.A. Fink, A.J. Trapani, R.L. Webb, P.A. Zane and R.E. Chatelain. CGS 30440: a dual inhibitor
of angiotensin-converting enzyme and neutral endopeptidase 24.11. Cardiovasc. Drug Rev. 17: 16-39, 1999.
6. D.S. Cohen, J.E. Mathis, R.A. Dotson, S.C. Graybill and N.J. Wosu. The protective effects of CGS 30440, a
combined angiotensin converting enzyme (ACE) inhibitor and neutral endo-peptidase inhibitor, a model of
chronic renal failure: a comparison with ACE inhibition. J. Cardiovasc. Pharm.32: 87-95, 1998.
7. I. Vlattas, J. Dellureficio, D.S. Cohen, W. Lee, F. Clarke, R. Dotson, J. Mathis and H. Zoganas. Thia-
prostanoid analogs with combined thromboxane receptor antagonist-thromboxane synthase inhibitor
activities: synthesis and pharmacological evaluation. Bioorg. Med. Chem. Let. 4: 2067-2072, 1994.
8. I. Vlattas, J. Dellureficio, D.S. Cohen, W. Lee, F. Clarke, R. Dotson, J. Mathis and H. Zoganas. Oxa-
prostanoid analogs: identification of an orally effective dual thromboxane receptor antagonist-thromboxane
synthase inhibitor. Bioorg. Med. Chem. Let. 4: 2073-2076, 1994.
9. R.W. Olson, R. Dotson, J. Mathis, D.S. Cohen and R.L. Webb. Beneficial effects of combined thromboxane
synthase inhibition and receptor blockade in a canine model of coronary thrombosis. Eur. J. Pharmacol. 236:
75-87, 1993.
10. S.S. Bhagwat, C. Gude, D.S. Cohen, R. Dotson, J. Mathis, W. Lee and P. Furness. Thromboxane receptor
antagonism combined with thromboxane synthase inhibition 5. Synthesis and evaluation of enantiomers of 8-
4 chlorophenylsulfonylamino-4-3-pyridinylalkyloctanoic acid. J. Med. Chem. 36: 205-210, 1993.
11. A.J. Main, S.S. Bhagwat, C. Boswell, R. Goldstein, C. Gude, D.S. Cohen, P. Furness, W. Lee and M.
Louzan. Thromboxane receptor antagonism combined with thromboxane synthase inhibition.3.
Pyridinylalkyl-substituted 8-[(arysulfonyl)amino]octanoic acids. J. Med. Chem. 35: 4366-4372, 1992.
12. D.S. Cohen, D.N. McMartin, M.P. Marietta, P.A. Zane and R.W. Lappe. CGS 22652: a new potent
thromboxane A2 receptor antagonist with selective thromboxane A2 inhibitory properties. Cardiovasc. Drug
Rev. 10: 379-391, 1992.
13. S.S. Bhagwat, C. Boswell, C. Gude, N. Contardo, D.S. Cohen, J. Mathis, R. Dotson, W. Lee and
S. Shetty. Thromboxane receptor antagonism combined with thromboxane synthase inhibition 6. 4-substituted
3 pyridinylalkanoic acids. Bioorg. Med. Chem. Lett. 2: 1619-1622, 1992.
9. David S. Cohen Ph.D. Curriculum Vitae 9
14. S.S. Bhagwat, D.M. Roland, A.J. Main, C. Gude, K. Grim, R. Goldstein, D.S. Cohen, R. Dotson, J. Mathis
and W. Lee. Thromboxane receptor antagonism combined with thromboxane synthase inhibition 7.
Pyridinylalkyl-substituted arylsulfonylamino arylalkanoic acids. Bioorg. Med. Chem. Lett. 2: 1623-1626,
1992.
15. S.S. Bhagwat, C. Gude, C. Boswell, N. Contardo, D.S. Cohen, R. Dotson, J. Mathis, W. Lee, P. Furness and
H. Zoganas. Thromboxane Receptor antagonism combined with thromboxane synthase inhibition 4. 8-4
Chlorophenylsulfonyl-4-3-3-pyridinylpropyloctanoic acid and analogs. J. Med. Chem. 35: 4373-4383, 1992.
16. A.J. Main, S.S. Bhagwat, C. Boswell, R. Goldstein, C. Gude, D.S. Cohen, P. Furness, W. Lee and M.
Louzan. Thromboxane Receptor antagonism combined with thromboxane synthase inhibition 3.
Pyridinylalkyl-substituted 8 arylsulfonylaminooctanoic acids. J. Med. Chem. 35: 4366-4372, 1992.
17. A.J. Main, R. Goldstein, D.S. Cohen, P. Furness and W. Lee. Thromboxane Receptor antagonism combined
with thromboxane synthase inhibition 2. Synthesis and biological activity of 8-benzenesulfonamido-7-
3pyridinyloctanoic acid and related compounds. J. Med. Chem. 35: 4362-4365, 1992.
18. S.S. Bhagwat, C. Gude, D.S. Cohen, W. Lee, P. Furness and F.H. Clarke. Thromboxane Receptor
antagonism combined with thromboxane synthase inhibition.1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic
acids. J. Med. Chem. 34: 1790-1797, 1991.
19. D.S. Cohen, E.C. Ku, E.F. Kimble, H.B. Renfroe and E.F. Smith. CGS 15435A, a thromboxane synthetase
inhibitor with an extended duration of action - a comparison with dazoxiben. Eur. J. Pharmacol. 133: 265-
273, 1987.
20. D.S. Cohen, D.I. Cargill, R.G. VanValen, J.J. Klimek and R.P. Levin. Aggregation, release and
desensitization induced in platelets from 5 species by platelet activating factor (PAF). Thromb. Haeomostas.
49: 204-207, 1983.
21. H.J. Weiss, H.R. Baumgartner, T.B. Tschopp, V.T. Turitto and D.S. Cohen. Correction by factor VIII of the
impaired platelet adhesion to subendothelium in von Willebrand disease. Blood 38: 297-301, 1978.
Abstracts:
1. D.S. Cohen, J.E. Mathis, R.A. Dotson, S. Graybill and J.L. Robertson. The combination of valsartan, an AII
antagonist, with benazepril, an ACE inhibitor, in rats with reduced renal mass: benefits over monotherapy.
2nd
Intl Symp on AII Antagonism, Feb, 1998.
2. D.S. Cohen, J.E. Mathis, R.A. Dotson, S. Graybill and J.L. Robertson. The lack of efficacy of endothelin
(ET) antagonism in rats with reduced renal mass. FASEB J. 12:663, 1998.
3. D.S. Cohen, J.E. Mathis, R. Dotson, S. Graybill and J.L. Robertson. The effects of valsartan (Va), an
angiotensin II receptor antagonist, plus benazepril (B), an ACEI on renal function in the rat remnant kidney
model. JASN 7: 6, 1996.
4. D.S. Cohen, J.E. Mathis, R.A. Dotson, S.C. Graybill and N.J. Wosu, Improved efficacy of a combination of
angiotensin converting enzyme inhibition (ACEI) and neutral endopeptidase inhibition (NEPI) over ACEI
alone in a model of chronic renal failure. JASN 6: 1011, 1995.
5. D.S. Cohen, J.E. Mathis and R.A. Dotson. GEA 3175, a novel new nitric oxide (NO) donor: a comparison
with sodium nitroprusside. FASEB J. 9: A923, 1995.
10. David S. Cohen Ph.D. Curriculum Vitae 10
6. R.A. Dotson, J.E. Mathis, H.H. Hsu and D.S. Cohen. Benazepril (BZ), an angiotensin converting enzyme
inhibitor, improves kidney function in a model of chronic renal failure in spontaneously hypertensive rats
(SHR). FASEB J. 9: A685, 1995.
7. S.C. Graybill, R.A. Dotson, J.E. Mathis, H.H. Hsu and D.S. Cohen. The dose-dependent effects of
benazepril, an angiotensin converting enzyme inhibitor, on the improvement of renal function in chronic
renal failure in 5/6 renal ablated normotensive Sprague-Dawley rats. FASEB J. 9: A685, 1995.
8. J.E. Mathis, R.A. Dotson, S.C. Graybill, H.H. Hsu and D.S. Cohen. Preservation of renal function in a model
of chronic renal failure: the effects of angiotensin converting enzyme inhibition (ACEI) vs. neutral
endopeptidase inhibition (NEPI). FASEB J. 9: A686, 1995.
9. J. Rediske, D. Cohen, J. Mathis, R.L. Goldberg, S. Spirito, R. Ghai, C. Berry and C. Koehne. The inducible
nitric oxide (NO) synthesis pathway in articular chondrocytes. Arthritis and Rheumatism 36: R36, 1993.
10. R.A. Dotson, J.E. Mathis and D.S. Cohen. Characterization of two nitric oxide (NO) releasing agents in
arterial and venous tissue. FASEB J. 7: A259, 1993.
11. J.E. Mathis, R.A. Dotson and D.S. Cohen. Sodium nitroprusside (SNP), SIN-1 and glyceryl trinitrate (GTN):
an in vitro comparison of their nitric oxide releasing characteristics and their antiplatelet activity. FASEB J.
7: A261, 1993.
12. D.S. Cohen, R.A. Dotson, J.E. Mathis, H.C. Zoganas, J.P. Simke, R.W. Olson, S.S. Bhagwat and R.L. Webb.
CGS 23305: in vivo and ex vivo characterization of a thromboxane (Tx) A2 receptor antagonist/Tx synthase
inhibitor (TxSI). FASEB J. 6: A999, 1992.
13. R. Dotson, D. Cohen, J. Mathis, P. Furness, W. Lee, S. Bhagwat and C. Gude. CGS 23305: in vitro
characterization of a potent thromboxane A2/prostaglandin H2 (TxA2/PGH2) receptor antagonist and
thromboxane synthase inhibitor. FASEB J. 6: A1599, 1992.
14. D.S. Cohen, S. Bhagwat, R. Dotson, J. Mathis, P. Furness, M. Louzan, W. Lee, J. Peppard and C. Gude. In
vitro characterization of CGS 22652, a combined thromboxane receptor antagonist (TXRA)/thromboxane
synthase inhibitor (TXSI). Thromb. Haemostas. 65: 1372, 1991.
15. D.S. Cohen, R. Dotson, J. Mathis, H. Zoganas, W.M. Coram, M. Louzan and S. Bhagwat. The effects of
CGS 22652, a potent dual thromboxane receptor antagonist (TXRA)/thromboxane synthase inhibitor (TXSI),
in vivo. Thromb. Haemostas. 65: 1734, 1991.
16. R.L. Webb, R.W. Olson, R. Dotson, J. Mathis and D.S. Cohen. Beneficial effects of CGS 22652, a
thromboxane receptor antagonist/thromboxane synthase inhibitor as an adjunct to streptokinase (SK) therapy
in a canine model of coronary thrombosis. Thromb. Haeomostas. 65: 1177, 1991.
17. S.S. Bhagwat, A.J. Main, C. Gude, C. Boswell, N. Contardo, R. Goldstein, D.S. Cohen, R. Dotson, M.
Louzan, J. Mathis, W. Lee, P. Furness, L. Autry, W. Coram and H. Zoganas. Thromboxane receptor
antagonism combined with thromboxane synthase inhibition. Synthesis and evaluation of CGS 22652 and its
analogs. Gordon Conference, 1991.
18. R. W. Olson, D.S. Cohen and R.L. Webb. Efficacy of thromboxane (TX) modulators as adjuncts to
streptokinase (SK) therapy. Arteriosclerosis 10: A942, 1990.
19. D.S. Cohen, E.F. Kimble, E.F. Smith III, R.W. Olson, G.G. Bastastini, E.C. Ku and H.B. Renfroe. CGS
14854, a potent selective long-acting thromboxane synthetase inhibitor is effective in rabbits, dogs and
monkeys. Fed. Proc. 45: 924, 1986.
11. David S. Cohen Ph.D. Curriculum Vitae 11
20. D.S. Cohen, T.D. Oglesby and E.C. Ku. Synergistic inhibition of platelet function in vivo by a thromboxane
synthetase inhibitor and modulator of cAMP. Thromb. Haemostas. 54: 133, 1985.
21. D.S. Cohen, H.J. Povalski, R.K. Rinehart, C. Tsai, B.W. Barclay, D. VanOrsdell and Y. Sakane. Inhibition
of thromboxane A2 (TXA2) synthetase causes endoperoxide shunting towards PGI2 and PGE2 synthesis in
canine whole blood. Fed. Proc. 42: 640, 1983.
22. D.S. Cohen, H.J. Povalski, R.K. Rinehart, C. Tsai, B.W. Barclay, D. VanOrsdell and Y. Sakane.
Thromboxane A2 (TXA2) synthetase inhibition results in endoperoxide shunting towards PGI2 and PGE2
synthesis in canine whole blood. Thromb. Haemostas. 50: 285, 1983.
23. D.S. Cohen, J.M. Strohschein, R.N. Saunders and D.I. Cargill. Platelet factor 4 release from unstimulated
human platelets. Thromb. Haemostas. 46: 132, 1981.
24. D.S. Cohen, D.I. Cargill, R. VanValen, M.L. Lee and R.N. Saunders. Platelet activating factor (PAF) -
induced aggregation and release responses in vitro in 3 species. Thromb. Haemostas. 46: 292, 1981.
25. V.T. Turitto, H.J. Weiss and D.S. Cohen. Interaction of human platelets with subendothelium: implications
for measurement of defects in platelet function. Thromb. Haemostas. 38: 297, 1977.